<DOC>
	<DOCNO>NCT00368173</DOCNO>
	<brief_summary>STUDY OBJECTIVE To evaluate safety , tolerability , efficacy , growth velocity ( statural growth ) , rhIGF-I/rhIGFBP-3 administer 12 month pre-pubertal child adolescents GHIS . STUDY DESIGN This study open-label , multi-center clinical trial evaluate safety effectiveness rhIGF-I/rhIGFBP-3 increase rate growth administer daily 12 month child adolescent growth hormone insensitivity syndrome ( GHIS ) Laron Syndrome . At end initial twelve-month treatment period , additional safety long-term efficacy data assess second 12 month treatment period .</brief_summary>
	<brief_title>IGF-I/IGFBP-3 Therapy Children Adolescents With Growth Hormone Insenitivity Syndrome ( GHIS ) Such Laron Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Laron Syndrome</mesh_term>
	<criteria>1 . A diagnosis GHIS Laron syndrome , 2 . 2 18 year age , 3 . Height le equal 3SD age , 4 . Prepubertal , define Tanner breast stage 1 testis volume &lt; 4mL 1 . Children puberty , 2 . Diagnosed malignancy , 3 . A diagnosis diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>